GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
…, D Chappell, T Sahmoud, C Durrant… - Blood, The Journal …, 2019 - ashpublications.org
Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics;
however, its application is limited by the associated toxicities. These include cytokine release …
however, its application is limited by the associated toxicities. These include cytokine release …
GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study
…, D Chappell, O Ahmed, R Sakemura, C Durrant… - Mayo Clinic …, 2020 - Elsevier
… Dababneh MD a , Gabrielle Chappell l , Dale Chappell MD, MBA l , Omar Ahmed PharmD
l , Reona Sakemura MD, PhD d e , Cameron Durrant MD, MBA l , Saad S. Kenderian MD d e f …
l , Reona Sakemura MD, PhD d e , Cameron Durrant MD, MBA l , Saad S. Kenderian MD d e f …
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
…, VM Catterson, WS Aronstein, C Durrant… - The Lancet …, 2022 - thelancet.com
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage …
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage …
Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia
…, A Tefferi, A Lo, T Shih, C Durrant… - Blood, The Journal …, 2020 - ashpublications.org
In this phase 1 trial, inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF)
was associated with clinically meaningful responses in 5 of 15 patients with relapsed or …
was associated with clinically meaningful responses in 5 of 15 patients with relapsed or …
[HTML][HTML] Lenzilumab efficacy and safety in newly hospitalized Covid-19 subjects: results from the live-air phase 3 randomized double-blind placebo-controlled trial
BACKGROUND: Severe COVID-19 pneumonia results from a hyperinflammatory immune
response (cytokine storm, CS), characterized by GM-CSF mediated activation and trafficking of …
response (cytokine storm, CS), characterized by GM-CSF mediated activation and trafficking of …
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity
…, EE Tapper, EL Siegler, D Chappell, C Durrant… - Leukemia, 2022 - nature.com
Inhibitory myeloid cells and their cytokines play critical roles in limiting chimeric antigen
receptor T (CART) cell therapy by contributing to the development of toxicities and resistance …
receptor T (CART) cell therapy by contributing to the development of toxicities and resistance …
First clinical use of lenzilumab to neutralize GM-CSF in patients with severe and critical COVID-19 pneumonia
…, D Chappell, O Ahmed, R Sakemura, C Durrant… - Medrxiv, 2020 - medrxiv.org
Background In COVID-19, high levels of granulocyte macrophage-colony stimulating factor (GM-CSF)
and inflammatory myeloid cells correlate with disease severity, cytokine storm, and …
and inflammatory myeloid cells correlate with disease severity, cytokine storm, and …
ATIM-23. Preliminary findings of a phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma
INTRODUCTION Alkylating agents such as Temozolomide (TMZ) significantly upregulate
stress-induced NKG2D ligands targeted by innate immune effector cells. Genetic modification …
stress-induced NKG2D ligands targeted by innate immune effector cells. Genetic modification …
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR'trial
…, F Cerasoli, A Kilcoyne, D Chappell, C Durrant… - Thorax, 2023 - thorax.bmj.com
Objective COVID-19 severity is correlated with granulocyte macrophage colony-stimulating
factor (GM-CSF) and C reactive protein (CRP) levels. In the phase three LIVE-AIR trial, …
factor (GM-CSF) and C reactive protein (CRP) levels. In the phase three LIVE-AIR trial, …
Early lenzilumab treatment of COVID-19 patients using c-reactive protein as a biomarker improves efficacy: results from the phase 3 'LIVE-AIR'trial
…, F Cerasoli, A Kilcoyne, D Chappell, C Durrant… - MedRxiv, 2022 - medrxiv.org
Objective The LIVE-AIR trial demonstrated that the anti-GM-CSF monoclonal antibody,
lenzilumab improved the likelihood of survival without invasive mechanical ventilation (SWOV) in …
lenzilumab improved the likelihood of survival without invasive mechanical ventilation (SWOV) in …